Single Bolus Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Bolus Infusion Alteplase in Patients With AIS


Phase 3 Results N/A

Summary of Purpose

The aim of the study is to determine if single-bolus recombinant nonimmunogenic staphylokinase is effective and save thrombolytic agent in with ischemic stroke in comparison to alteplase.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 11 May 2017.

15 Jul 2016 10 May 2017 27 Dec 2018 27 Dec 2018 1 May 2017 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics




Trial Design

Not available


  • Evgenii I Gusev, MD, Prof